Document:

Warrant to purchase shares of Common Stock

 Exhibit 4.1 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND
PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE
REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT TO PURCHASE STOCK 

 

			
	 Corporation:
	 	diaDexus, Inc., a Delaware corporation
	 Number of Shares:
	 	480,769
	 Class of Stock:
	 	Common Stock
	 Warrant Price:
	 	$0.26 per share
	 Issue Date:
	 	September 23, 2011
	 Expiration Date:
	 	September 23, 2018 (Subject to Section 4.1)

 THIS WARRANT TO PURCHASE STOCK (THIS “WARRANT”) CERTIFIES THAT, for good and valuable
consideration, the receipt of which is hereby acknowledged, COMERICA BANK, a Texas banking association, or its assignee (“Holder”), is entitled to purchase the number of fully paid and nonassessable shares of the class of securities (the
“Shares”) of diaDexus, Inc. (the “Company”) at the Warrant Price, all as set forth above and as adjusted pursuant to the terms of this Warrant, subject to the provisions and upon the terms and conditions set forth in this
Warrant. 
 ARTICLE 1 
 EXERCISE 
 1.1        Method of
Exercise. Holder may exercise this Warrant by a duly executed Notice of Exercise in substantially the form attached as Appendix I to the principal office of the Company (or such other appropriate location as Holder is so instructed by the
Company). Holder shall also deliver to the Company a check, wire transfer (to an account designated by the Company) or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 

1.2        Intentionally Omitted. 

1.3        Delivery of Certificate and New Warrant. Within 30 days after Holder exercises
this Warrant and the Company receives payment of the aggregate Warrant Price, the Company shall deliver, or cause its transfer agent to deliver, to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised and has
not expired, a new warrant representing the Shares not so acquired. 

1.4        Replacement of Warrants. In the case of loss, theft or destruction of this
Warrant, upon delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company at its expense shall execute and deliver, in lieu
of this Warrant, a new warrant of like tenor. 
 1.5        Acquisition of the
Company. 
 1.5.1        “Acquisition.” For the purpose of this
Warrant, “Acquisition” means (a) any sale, license, or other disposition of all or substantially all of the assets (including intellectual property) of the Company, or (b) any reorganization, consolidation, merger, sale of the
voting securities of the Company or other transaction or series of related transactions where the holders of the Company’s securities before the transaction or series of related transactions beneficially own less than 50% of the outstanding
voting securities of the surviving entity after the transaction or series of related transactions. 

  
 1 

 1.5.2        Treatment of Warrant in the Event of
an Acquisition. The Company shall give Holder written notice at least 10 days prior to the closing of any proposed Acquisition. The Company will use commercially reasonable efforts to cause (i) the acquirer of the Company,
(ii) successor or surviving entity or (iii) parent entity in an Acquisition (the “Acquirer”) to assume this Warrant as a part of the Acquisition. 

(a)        If the Acquirer assumes this Warrant, then this Warrant shall be
exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent
closing. The Warrant Price shall be adjusted accordingly, and the Warrant Price and number and class of Shares shall continue to be subject to adjustment from time to time in accordance with the provisions hereof. 

(b)        If the Acquirer refuses to assume this Warrant in connection with the
Acquisition, the Company shall give Holder written notice of that fact at least ten (10) days prior to the closing of the Acquisition of such fact. In such event, notwithstanding any other provision of this Warrant to the contrary, Holder may
immediately exercise this Warrant in the manner specified in this Warrant with such exercise effective immediately prior to closing of the Acquisition. If Holder elects not to exercise this Warrant, then this Warrant will terminate immediately prior
to the closing of the Acquisition. Notwithstanding any other provision of this Warrant to the contrary if the Acquirer refuses to assume this Warrant in connection with such Acquisition, other than in connection with an Excluded Acquisition (as
defined below), then effective as of the date that is ten (10) days prior to the closing of such Acquisition, the Holder shall have the option to put this Warrant to the Company for a per Share amount equal to the difference between the
Acquisition consideration payable for one Share and the Warrant Price. As used herein, an “Excluded Acquisition” means, an Acquisition where the consideration that the holders of the Shares are entitled to receive on account of the Shares
consists entirely of cash and/or shares of common stock that are publicly traded on a national exchange and where the shares, if any, receivable by the Holder of this Warrant were the Holder to exercise this Warrant in full immediately prior to the
closing of such Acquisition may be publicly re-sold by the Holder in their entirety within the three (3) months following such closing pursuant to Rule 144 or an effective registration statement under the Act. 

ARTICLE 2 

ADJUSTMENTS TO THE SHARES 
 2.1        Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its common stock payable in common stock, or other securities, or
subdivides the outstanding common stock into a greater amount of common stock, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would
have been entitled had Holder owned the Shares of record as of the date the dividend or subdivision occurred. 

2.2        Reclassification, Exchange or Substitution. Upon any reclassification,
exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the
number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange, substitution, or other event. The Company or its successor shall
promptly issue to Holder a new warrant for such new securities or other property. The new warrant shall provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including,
without limitation, adjustments to the Warrant Price and the number of securities or property issuable upon exercise of the new warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges,
substitutions, or other events. 
 2.3        Adjustments for Combinations, Etc.
If the outstanding Shares are combined or consolidated, by reclassification, reverse split or otherwise, into a lesser Number of Shares, the Warrant Price shall be proportionately increased. If the outstanding Shares are split or multiplied, by
reclassification or otherwise, into a greater Number of Shares, the Warrant Price shall be proportionately decreased. 

  
 2 

 2.4        Intentionally Omitted. 

2.5        No Impairment. The Company shall not, by amendment of its Certificate of
Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or
performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this
Article 2 against impairment. 
 2.6        Certificate as to Adjustments. Upon
each adjustment of the Warrant Price, the Company at its expense shall promptly compute such adjustment, and furnish Holder with a certificate signed by its Chief Financial Officer setting forth such adjustment and the facts upon which such
adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant Price. 

2.7        Fractional Shares. No fractional Shares shall be issuable upon exercise of this
Warrant and the Number of Shares to be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise of this Warrant, the Company shall eliminate such fractional share interest by paying Holder an
amount computed by multiplying the fractional interest by the fair market value, as determined by the Company’s Board of Directors, of a full Share. 
 ARTICLE 3 
 REPRESENTATIONS AND COVENANTS OF THE COMPANY 

3.1        Representations and Warranties. The Company hereby represents and warrants to,
and agrees with, the Holder as follows: all Shares which may be issued upon the exercise of the purchase right represented by this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon issuance, be duly authorized,
validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws 

3.2        Notice of Certain Events. If the Company proposes at any time (a) to
declare any dividend or distribution upon its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription pro rata to the holders of any class or series of its stock any
additional shares of stock of any class or series or other rights; (c) to effect any reclassification or recapitalization of stock; or (d) to merge or consolidate with or into any other corporation, or sell, lease, license, or convey all
or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder (1) at least 10 days prior written notice of the date on which a record will be taken for such
dividend, distribution, or subscription rights (and specifying the date on which the holders of stock will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in (a) and (b) above; and
(2) in the case of the matters referred to in (c) and (d) above at least 10 days prior written notice of the date when the same will take place (and specifying the date on which the holders of stock will be entitled to exchange their
stock for securities or other property deliverable upon the occurrence of such event). Upon request, the Company shall provide Holder with such information reasonably necessary for Holder to evaluate its rights as a holder of this Warrant or Warrant
Shares in the case of matters referred to (a), (b), (c) and (d) herein above. 

3.3        Information Rights. So long as the Holder holds this Warrant and/or any of the
Shares, the Company shall deliver to the Holder (a) promptly after mailing, copies of all communications, information and/or communiqués to the shareholders of the Company, (b) within one hundred twenty (120) days after the end
of each fiscal year of the Company, the annual audited financial statements of the Company certified by independent public accountants of recognized standing and (c) within forty-five (45) days after the end of each of the first three
quarters of each fiscal year, the Company’s quarterly, unaudited financial statements, to the extent that any of such information has not been publicly filed with the Securities and Exchange Commission. In addition, and without limiting the
generality of the foregoing, so long as the Holder holds this Warrant and/or any of the Shares, the Company shall afford to the Holder the same access to information concerning the Company and its business and financial condition as would be
afforded to a holder of the class of Shares under applicable state law and/or any agreement with any holder of the class of Shares. 

  
 3 

 ARTICLE 4 
 MISCELLANEOUS 
 4.1        Term;
Exercise Upon Expiration. This Warrant is exercisable in whole or in part, at any time and from time to time on or before the Expiration Date set forth above. The Company agrees that Holder may terminate this Warrant, upon notice to the Company,
at any time in its sole discretion. 
 4.2        Legends. This Warrant and the
Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. 
 4.3        Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable,
directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee. The Company shall not
require Comerica Bank (“Bank”) or a Bank Affiliate (as defined herein) to provide an opinion of counsel or investment representation letter if the transfer is to Bank’s parent company, Comerica Incorporated (“Comerica”), or
any other affiliate of Bank (“Bank Affiliate”). 
 4.4        Transfer
Procedure. After receipt of the executed Warrant, Bank will transfer all of this Warrant to Comerica Ventures Incorporated, a non-banking subsidiary of Comerica and a Bank Affiliate (“Ventures”). Subject to the provisions of
Section 4.3, Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company notice of the
portion of this Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to the Company for reissuance to the transferee(s) (and Holder, if applicable); provided,
however, that Holder may transfer all or part of this Warrant to its affiliates, including, without limitation, Ventures, at any time without notice or the delivery of any other instrument to the Company, and such affiliate shall then be entitled to
all the rights of Holder under this Warrant and any related agreements, and the Company shall cooperate fully in ensuring that any stock issued upon exercise of this Warrant is issued in the name of the affiliate that exercises this Warrant. The
terms and conditions of this Warrant shall inure to the benefit of, and be binding upon, the Company and the holders hereof and their respective permitted successors and assigns. 

4.5        Notices. All notices and other communications from the Company to the Holder,
or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, or sent via a nationally recognized overnight courier service, fee prepaid, or on the first business
day after transmission by facsimile, at such address or facsimile number as may have been furnished to the Company or the Holder, as the case may be, in writing by the Company or such Holder from time to time. Effective upon the receipt of executed
Warrant and initial transfer described in Article 4.4 above, all notices to the Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 

Comerica Ventures Incorporated 
 Attn: Warrant Administrator 
 1717 Main Street, 5th Floor, MC 6406 

  
 4 

 Dallas, Texas 75201 

Facsimile No. (214) 462-4459 
 All notices to the Company shall be addressed as follows: 
 diaDexus, Inc.

 343 Oyster Point Blvd. 
 South San Francisco, CA 94080 
 Attn: Chief Financial Officer 

Facsimile No.: (650) 246-6499 
 4.6        Amendments; Waiver. This Warrant and any term hereof may be amended, changed, waived, discharged or terminated only by an instrument in writing
signed by the party against which enforcement of such amendment, change, waiver, discharge or termination is sought. 

4.7        Attorneys’ Fees. In the event of any dispute between the parties
concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

4.8        Governing Law. This Warrant shall be governed by and construed in accordance
with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 
 [Balance
of Page Intentionally Left Blank] 

  
 5 

 IN WITNESS WHEREOF, this Warrant is issued as of the Issue Date set forth above. 

 

			
	diaDexus, Inc.
		
	By:	 	/s/ James P. Panek
		
	Name:	 	James P. Panek
		
	Title:	 	CEO

  

			
		
	By:	 	 
		
	Name:	 	 
		
	Title:	 	 

 [Signature Page to Warrant to Purchase Stock] 

  
 6 

 APPENDIX I 
 NOTICE OF EXERCISE 
 1.        The
undersigned hereby elects to purchase ______________ shares of the ______________ stock of diaDexus, Inc. pursuant to the terms of the attached Warrant, and tenders herewith payment of the purchase price of such shares in full. 

2.        Please issue a certificate or certificates representing said shares in the name of the
undersigned or in such other name as is specified below: 
 Comerica Ventures Incorporated 

Attn: Warrant Administrator 
 1717 Main Street, 5th Floor, MC 6406 
 Dallas, Texas 75201 

Facsimile No. (214) 462-4459 
 3.        The undersigned represents it is acquiring the shares solely for its own account and not as a nominee for any other party and not with a view toward the
resale or distribution thereof except in compliance with applicable securities laws. 
 COMERICA VENTURES INCORPORATED or 

Assignee 

	
	  
	   

	 (Signature)

	  
	   

	 (Name and Title)

	  
	   

	 (Date)

  
 Appendix I

 Page 7Offer Letter

 Exhibit 10.2 
 September 20, 2011 
 Brian Ward 
 Dear Brian, 
 On behalf of diaDexus, Inc., I am pleased to extend to you an offer of continued
employment for the position of Chief Executive Officer (CEO) reporting to the diaDexus Board of Directors. We are very enthusiastic about having you expand your role within the company and leading the executive team and diaDexus toward realizing its
potential. This letter sets forth some important terms and conditions of your continuing employment with diaDexus. Please read it carefully. 
 As Chief Executive Officer, you will have the duties and responsibilities commensurate with the duties and responsibilities customarily associated with such position and such other duties and
responsibilities as may be prescribed by the diaDexus’ Board of Directors (the “Board”). You will be expected to devote virtually 100% of your business time and attention to this position, but as an exempt salaried employee, you must
work such hours as may be required by the nature of your work assignments and will not be eligible for overtime pay. Your start date will be as soon as can be arranged. 
 Your monthly salary will be $31,667 ($380,000 on an annualized basis) less required withholding taxes and authorized deductions. Your salary will be periodically reviewed by the Compensation Committee of
the Board, consistent with diaDexus’ compensation review practices. 
 You will be eligible to participate in the diaDexus bonus plan and
can earn up to 50% of your annual salary based on achieving specific goals and objectives established by the Compensation Committee or the Board. 
 You will be entitled to all rights and benefits for which you are eligible under the terms and conditions of the standard Company benefits and compensation practices that may be in effect from time to
time and are provided by the Company to its executive employees generally. Your personal coverage under diaDexus’ benefit plans will become effective the first day of the next calendar month of full-time work with diaDexus following your start
date. 
 We will recommend to the Compensation Committee and Board that you be granted an additional option such that your total grants to
purchase shares of diaDexus Common Stock will total 1,700,000. The per share exercise price of the option will be equal to the fair market value of a share of diaDexus Common Stock on the date of grant. The options will vest such that the

 
total of the grants will be fully vested and exercisable on the fourth anniversary of your Commencement Date with diaDexus, July 1, 2011, subject to your continued employment by diaDexus
through each vesting date. The option is subject to Board approval and your execution of an agreement setting forth the full terms and conditions the grant. 
 Your employment with the Company is for no specified period and constitutes at will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is
free to conclude its employment relationship with you at any time, with or without cause, and with or without notice. At will employment also means that your job duties, title, responsibility, reporting level, work schedule, compensation and
benefits, as well as the Company’s personnel policies and procedures, may be changed at any time, in the sole discretion of diaDexus. The at will nature of your employment may only be changed in a written agreement signed by you and the
Chairman of the Board of Directors. Notwithstanding the foregoing, you will be entitled to enter into a Change in Control and Severance Agreement that will provide for severance benefits upon certain terminations of your employment with diaDexus.

 As a condition of your employment, you must carefully review, sign, and comply with the Employee Proprietary Information and Invention
Assignment Agreement if you have not already done so. Also as a condition of your employment, you agree to abide by the Company’s policies and procedures, as adopted from time to time, and to refrain from any activities that conflict with your
obligations to the Company. You represent that you do not have any agreements with any third parties (e.g., former employers), including but not limited to non-competition or proprietary information agreements, that will conflict with or limit your
ability to discharge your duties to diaDexus. You agree that, in the course of your work for diaDexus, you will not make any unauthorized use or disclosure of any proprietary information or materials of any third party (e.g., a former employer). In
addition, you agree that, during the term of your employment by diaDexus, you will not engage in any other employment, occupation, consulting or other business activity directly related to the business in which diaDexus is now involved or becomes
involved during the term of your employment (a “Competing Business”), nor will you engage in any other activities that conflict with your obligations to the Company. Notwithstanding anything herein to the contrary, you may serve in any
capacity with any civic, educational or charitable organization. 
 The Immigration Reform and Control Act of 1986 requires that every person
present to potential employers proof of identity and eligibility or authorization to accept employment in the United States. In order to comply with this law, and before you can become a diaDexus employee, you must provide appropriate
documentation to prove both your identity and legal eligibility to be employed by diaDexus. Acceptable forms of documentation are described on the attachment to this offer letter. Please be sure to bring this documentation with you on your first day
of employment. 
 This letter, (together with the Employee Proprietary Information and Inventions Agreement, your Change in Control and
Severance Agreement and any other formal agreements entered into between you and diaDexus) constitutes the complete and exclusive statement of your agreement with diaDexus concerning the subject matter hereof. It supersedes any other agreements or

 
promises made to you by anyone, whether oral or written, and it cannot be changed except in a written agreement, signed by you and the Chairman of the Board of Directors. 

We are very excited at the prospect of your joining us and to relying on your executive leadership of diaDexus. Please do not hesitate to contact me with
any questions. This offer will remain open until September 22 at which time it will expire if not previously accepted in writing. 
 To
indicate your acceptance of our offer, please sign and date one copy of this letter to me. 
 Sincerely, 

 

									
		    		 	AGREED AND ACCEPTED
				
	By:	 	/s/ Lori Rafield	    		 	/s/ Brian E. Ward
	Lori Rafield	    		 	Brian E. Ward
	Chairman of the Board	    		 	
					
	Date:	 	9/22/11	    		 	Date:	 	09/21/2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00196-of-00352.parquet"}]]